FYR Bio
FYR Bio is a private biotechnology company that provides AI-enabled liquid biopsy biomarker discovery and clinical trial support services to pharmaceutical, biotech, and academic medical center partners using its proprietary extracellular vesicle enrichment and multiomic analytics platform (EV-Omics).
- Company typePrivate
- Founded-
- HeadquartersMissoula, United States
- Headcount11–50
- GTM typeB2B
- OfferingServices
What FYR Bio does
FYR Bio (legal entity FYR Diagnostics, Inc.) is a private biotechnology company headquartered in Missoula, Montana, that operates an extracellular vesicle (EV)-based liquid biopsy platform called EV-Omics (EVO). The company's core differentiator is its proprietary SPARCs (Selective Protein Affinity Reagent Chemistries) enrichment technology, which isolates disease- or tissue-associated EV subpopulations from peripheral blood to solve the signal-to-noise problem that limits conventional liquid biopsy approaches. AI-enabled multiomic analytics then process RNA and protein data from these enriched vesicles to produce disease biomarkers, with peer-reviewed clinical validation showing 89% sensitivity and 100% specificity (AUC 0.99) for distinguishing adult malignant gliomas from healthy controls.
FYR operates as a B2B service provider serving pharmaceutical and biotech drug developers, academic medical centers, and clinical research programs. Primary applications are biomarker discovery, patient stratification, pharmacodynamic readouts, and treatment response monitoring across neuro-oncology (e.g., glioblastoma), neurodegeneration (e.g., Parkinson's disease), and broader solid tumor oncology. The company holds active CLIA certification (CLIA #27D2190551) and maintains HIPAA compliance, enabling clinical-grade diagnostic operations at its Montana laboratory. Named collaborations include NuvOx Therapeutics (Phase IIb RESTORE glioblastoma trial supported by an NCI SBIR grant) and Mayo Clinic (Parkinson's disease biomarkers). Compute infrastructure is provided through a CIQ Fuzzball integration that scales AI pipelines to production-grade throughput.
The business model is professional services-based: revenue is generated through custom project agreements with enterprise pharma and biotech partners, supplemented by non-dilutive SBIR grant funding. Pricing is not publicly disclosed and contracts operate on a multi-year, custom-tailored basis. The company was founded prior to 2021 and has raised approximately $8 million in venture capital as of September 2025 (Two Bear Capital, The Sontag Innovation Fund, Yuvaan Tiwari Foundation), plus a $1,976,897 NCI SBIR grant awarded in November 2025. Headcount is 11-50 employees and operations are U.S.-based, with go-to-market executed through direct business development outreach, scientific conference presentations, and peer-reviewed publications.
FYR Bio firmographics
Firmographics- Name
- FYR Bio
- Legal name
- FYR Diagnostics, Inc.
- Website
- https://fyr.bio
- Company type
- Private
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- FYR Bio is a private biotechnology company that provides AI-enabled liquid biopsy biomarker discovery and clinical trial support services to pharmaceutical, biotech, and academic medical center partners using its proprietary extracellular vesicle enrichment and multiomic analytics platform (EV-Omics).
- Ownership category
- akta.pro rank
FYR Bio industry classification
Industry- Product category
- Biomarker Discovery Services
- NAICS
- In-Vitro Diagnostic Substance Manufacturing (325413), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)
- SIC
- In Vitro & In Vivo Diagnostic Substances (2835), Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- Biomarker Discovery & Validation (omics, assay feasibility, clinical validation) (HLAAAMAA)
- akta.pro secondary industries
- Genomic & Multi-Omic Biomarkers (NGS panels, transcriptomics, proteomics, metabolomics) (HLAAAMAJ), Translational & Pharmacodynamic Biomarkers (MOA, target engagement, PD/PK-linked markers) (HLAAAMAD), Proteomics & Biomarker Analytical Testing (HLAGADAG), Bioanalytical & Biomarker CROs (PK/PD/Immunogenicity) (HLAGAAAD)
Keywords
Where FYR Bio is headquartered
LocationHeadquarters
- HQ city
- Missoula
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
FYR Bio business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
Revenue model
- Biomarker Discovery Services: FYR provides biomarker discovery and validation services to pharmaceutical and biotech partners through collaborative research agreements. Services include analysis of patient blood samples using the EV-Omics platform to identify and validate disease biomarkers for clinical trial support and therapeutic development.
- Clinical Trial Support: The company supports clinical trials through longitudinal biomarker analysis, pharmacodynamic readouts, and patient stratification services. Revenue generated through service agreements with drug development companies participating in Phase IIb trials and other clinical programs.
- SBIR Grant Funding: Non-dilutive funding from Small Business Innovation Research (SBIR) grants, including a $1,976,897 Direct-to-Phase II award from the National Cancer Institute supporting the liquid biopsy collaboration with NuvOx Therapeutics in glioblastoma trials.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Multi-year contract | Custom project-based pricing for pharmaceutical partners |
Go-to-market motion2 records
Distribution channels1 record
Marketing channels5 records
FYR Bio product offering
Product offeringCore offering
FYR Bio provides biomarker discovery and clinical trial support services to pharmaceutical and biotech partners through its EV-Omics (EVO) platform, which uses proprietary SPARCs enrichment technology and AI-enabled multiomic analysis of extracellular vesicles (EVs) from blood samples to identify RNA and protein biomarkers. The company's CLIA-certified laboratory supports longitudinal biomarker analysis, patient stratification, pharmacodynamic readouts, and treatment response monitoring across oncology, neuro-oncology, and neurodegeneration indications.
Product overview
FYR Bio offers a unified platform centered on its EV-Omics (EVO) technology, which combines proprietary SPARCs enrichment chemistry with AI-enabled multiomic analysis of extracellular vesicles from peripheral blood. The core EVO Platform serves as the primary discovery and detection engine for RNA and protein biomarkers, while SPARCs provides the foundational EV isolation technology that enables the platform to extract meaningful signals from the complex blood environment. Fuzzball (from CIQ) is integrated as a computational infrastructure layer that scales the EVO platform's analytics workflows for production-grade, reproducible biomarker discovery.
Differentiator
Problem solved
Functional benefit
Products and services
- EV-Omics (EVO) Platform
Quantifiable outcome
- 89% sensitivity and 100% specificity (AUC 0.99) in distinguishing adult malignant gliomas from healthy controls using brain-derived EV protein panels
- +2 more outcomes
Companies that use FYR Bio
Customer profileNamed customers2 records
Segments3 records
Ideal customer profiles2 records
FYR Bio technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability3 records
Feature3 records
FYR Bio partnerships and signals
Strategic signalPartnerships
Three partnerships are on record, tiered core and major.
- NuvOx TherapeuticscoreClinical collaboration supported by $1,976,897 NCI Direct-to-Phase II SBIR grant. FYR integrates EV-based liquid biopsy technology into NuvOx's Phase IIb RESTORE trial of NanO2 in glioblastoma. Project aims to identify biomarkers that reflect hypoxia biology, correlate with treatment exposure, and help differentiate pseudoprogression from true progression.
- CIQmajorTechnology integration partnership where CIQ's Fuzzball performance computing platform powers FYR's analytics workflows. Fuzzball enables FYR to implement and scale AI pipelines at 100x throughput with production-quality reproducibility. Both companies are Two Bear Capital portfolio companies, enabling transformative innovation across the life sciences ecosystem.
- Mayo CliniccoreKnow-how agreement to advance blood-based biomarker solutions for Parkinson's disease research and clinical applications. Collaboration aims to generate data to deepen understanding of PD progression and subtypes, discover EV biomarkers associated with Parkinson's disease, and develop tools with clinical and commercial applications.
Scale indicators4 records
Recent moves6 records
Expansion highlights5 records
FYR Bio competitors and assessment
Company assessmentBroad incumbents
- Foundation Medicine: Foundation Medicine (a Roche subsidiary) is a leading oncology molecular profiling and biopharma services company. It is a broad incumbent peer to FYR for pharma biomarker discovery and clinical trial companion diagnostic partnerships in oncology.
- Natera: Natera is a publicly-traded cell-free DNA and liquid biopsy company with oncology, transplant, and reproductive health franchises. It is a broad incumbent peer to FYR in the pharma services liquid biopsy market, particularly for oncology trial support.
- Guardant Health: Guardant Health is a leading liquid biopsy company with established pharma services (Guardant360, Reveal) for oncology. It is a broad incumbent peer to FYR's pharma biomarker services because it competes for the same pharma R&D and clinical trial biomarker budgets across oncology.
- NeoGenomics: NeoGenomics operates oncology-focused clinical laboratory and pharma services (including biomarker discovery and CDx). It is a broad incumbent peer competing with FYR for pharma biomarker and clinical trial work in oncology.
- Adaptive Biotechnologies: Adaptive Biotechnologies operates a clonal sequencing biomarker platform serving pharma drug development and clinical diagnostics. It is a broad incumbent peer: it competes with FYR for pharma biomarker discovery budgets, and FYR's new COO previously led molecular lab operations at Adaptive.
- Bio-Techne: Bio-Techne (including ExosomeDx) is a large life-sciences tools and diagnostics company with an EV-based diagnostics franchise (ExosomeDx). It is a broad incumbent peer: it competes in EV-based liquid biopsy for urology and oncology while offering a wider proteomics/reagents portfolio.
- Caris Life Sciences: Caris Life Sciences offers molecular profiling and AI-driven biomarker analytics (MI Profile, MI Cancer Seek) to oncologists and biopharma. It is a broad incumbent peer in pharma multiomic biomarker discovery and clinical trial services, overlapping with FYR's oncology biomarker offering.
Direct peers
- C2N Diagnostics: C2N Diagnostics commercializes blood-based biomarker assays for CNS disorders (e.g., PrecivityAD for Alzheimer's). It is a direct peer to FYR's Mayo Clinic Parkinson's program because both target CNS fluid biomarkers in blood, serving pharma and academic neurology customers.
- Quanterix: Quanterix offers ultra-sensitive protein biomarker measurement (Simoa) used in neuro-oncology and neurodegeneration research. It is directly comparable to FYR's EV-based proteomics discovery work, addressing similar pharma biomarker customers with blood-based immunoassay analytics.
Emerging players
- Personalis: Personalis provides tumor-informed liquid biopsy and molecular profiling services to oncology biopharma. It is an emerging player peer because it overlaps with FYR in pharma-facing multiomic biomarker services for oncology trials, but with a focus on ctDNA rather than EVs.
Market position
Strengths5 records
Weaknesses2 records
Competitive moat4 records
Key risks6 records
Key highlights7 records
Customer concentration
FYR Bio social profiles
Digital presenceFYR Bio compliance and trust
Trust signalCompliance2 records
FYR Bio financial estimates
Financial estimateRevenue estimate
Valuation estimate
FYR Bio leadership team
Management profileNumber of profiles
Profiles10 records
FYR Bio funding detail
Funding detailFunding overview
Funding rounds1 record
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
FYR Bio M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about FYR Bio
What does FYR Bio do?
FYR Bio provides biomarker discovery and clinical trial support services to pharmaceutical and biotech partners through its EV-Omics (EVO) platform, which uses proprietary SPARCs enrichment technology and AI-enabled multiomic analysis of extracellular vesicles (EVs) from blood samples to identify RNA and protein biomarkers. The company's CLIA-certified laboratory supports longitudinal biomarker analysis, patient stratification, pharmacodynamic readouts, and treatment response monitoring across oncology, neuro-oncology, and neurodegeneration indications.
Is FYR Bio a public or private company?
FYR Bio is a private company. It is classified as venture growth investor backed and is currently operating.
When was FYR Bio founded?
FYR Bio was founded in -1. It employs 11 to 50 people.
Where is FYR Bio based?
FYR Bio is headquartered in Missoula, United States, in the North America region.
How does FYR Bio make money?
Three revenue lines are on record. Biomarker Discovery Services are the primary driver. The others are clinical Trial Support and SBIR Grant Funding.
Who are FYR Bio's main competitors?
Broad incumbents on record are Foundation Medicine, Natera, Guardant Health, NeoGenomics, Adaptive Biotechnologies, Bio-Techne and Caris Life Sciences. Direct peers are C2N Diagnostics and Quanterix. Personalis is listed as an emerging player.
Does FYR Bio have an API?
No public API is recorded for FYR Bio.
What industry is FYR Bio in?
FYR Bio's product category is Biomarker Discovery Services. Its primary akta.pro industry code is HLAAAMAA, Biomarker Discovery & Validation (omics, assay feasibility, clinical validation), with a secondary code of HLAAAMAJ, Genomic & Multi-Omic Biomarkers (NGS panels, transcriptomics, proteomics, metabolomics). Its NAICS code is 325413 and its SIC code is 2835.